News

Portfolio Companies
in the News

Contego Medical Announces Start of Enrollment in Performance III Direct Transcarotid Access Stenting Trial

October 6, 2023

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

August 15, 2023

Impulse Dynamics Announces First Implant for CCM-D™ Clinical Trial

May 18, 2023

Miach Orthopaedics Launches BEAR® Implant Registry Study

May 2, 2023

Gynesonic Names Industry veteran skip baldino president and ceo, announces $25M financing to expand worldwide commercialization

April 11, 2023

Thryv Therapeutics Inc. Announces Completion of Initial Phase 1 Clinical Study and Beginning of Proof of Efficacy Study in Long QT Syndrome

March 14, 2023

Miach Orthopaedics Secures $40 Million Financing

January 25, 2023

Contego Medical Completes Enrollment of the PERFORMANCE II Carotid Stent Trial

November 14, 2022

Neuros Medical Announces Completion of QUEST Pivotal Trial 90-day Primary Endpoints

June 6, 2022

category

Medtech

Status

Current

headquarters

Halifax, Nova Scotia

website

Sound Blade Medical

Sound Blade Medical is a medical device company that is developing handheld ultrasound-guided histotripsy technology to treat a wide range of conditions. Histotripsy is a non-invasive, non-thermal ablation technology to selectively destroy tissue with unparalleled precision.

category

medtech

status

Current

headquarters

Plymouth, Minnesota

website

HistoSonics

HistoSonics has developed a system to destroy tumors completely non-invasively. Treatment is achieved using histotripsy, a novel form of energy that is safe, extremely precise, and able to be personalized for each patient. The initial indication is for treatment of liver tumors and the system is being studied in several other types of tumors.

category

MEDTECH

status

Exited/Public

headquarters

Redwood City, California

website

Gynesonics

Gynesonics is a medical device company committed to advancing women’s health by developing transcervical, uterus-preserving, incisionless technologies for diagnostic and therapeutic applications. The company’s Sonata system is the world’s first and only intrauterine fibroid ablation system clinically proven to reduce fibroid symptoms across a wide range of fibroid types, sizes, and uterine locations.